On 24 and 25 October 2019, the kick-off meeting for the VALUE-Dx ‘Clinical Studies’ work package was hosted at the Julius Centre of Health Sciences and Primary Care of the University Medical Center Utrecht in Zeist, the Netherlands.
Representatives from different community care settings, from the industry partners and from other work packages came together in preparation for the point prevalence audit survey which is planned to take place during the ‘high-peak’ winter season (January-March 2020) in 21 countries across Europe.
Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019
The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitrodiagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. The purpose of VALUE-Dx is to transform medical practice to achieve more personalised,